United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $467.55, for a total transaction of $1,870,200.00. Following the completion of the sale, the chief executive officer directly owned 130 shares in the company, valued at $60,781.50. This trade represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $4.67 during mid-day trading on Tuesday, reaching $476.59. 599,870 shares of the stock were exchanged, compared to its average volume of 591,927. The business’s 50 day moving average is $433.93 and its 200-day moving average is $351.26. The company has a market capitalization of $20.52 billion, a P/E ratio of 18.06, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $485.32.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the firm posted $6.39 EPS. The business’s revenue was up 6.8% on a year-over-year basis. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on UTHR. Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Oppenheimer upped their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Bank of America raised their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $503.90.

Institutional Trading of United Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics in the third quarter worth about $317,617,000. Norges Bank purchased a new position in United Therapeutics during the second quarter valued at $136,453,000. Invesco Ltd. boosted its position in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Finally, Nuveen LLC bought a new stake in United Therapeutics during the first quarter valued at about $83,533,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.